Rose, AngelaLucaccioni, HéloïseMarsh, KimberlyKirsebom, FrejaWhitaker, HeatherEmborg, Hanne-DortheBotnen, Amanda BoltO’Doherty, Mark G.Pozo, FranciscoShahul Hameed, SafrajAndrews, NickHamilton, MarkLauenborg Møller, KarinaTrebbien, RamonaMarques, Diogo F.P.European IVE group2026-01-142026-01-142025-02-20Euro Surveill. 2025 Feb;30(7):2500102. doi: 10.2807/1560-7917.ES.2025.30.7.2500102. Erratum in: Euro Surveill. 2025 Mar;30(11). doi: 10.2807/1560-7917.ES.2025.30.11.240320c1560-7917http://hdl.handle.net/10400.18/10696The 2024/25 influenza season in Europe is currently characterised by the co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness estimates from eight European studies conducted in 17 countries indicate an overall influenza A vaccine effectiveness of 32–53% in primary care settings and 33–56% in hospital settings, with some indications of lower effectiveness by subtype and higher effectiveness against influenza B (≥58% across settings). Where feasible, influenza vaccination should be encouraged and other preventive measures strengthened.engInfluenzaVaccineEffectiveness2024-2025EuropeDeterminantes da Saúde e da DoençaInfecções Respiratóriasjournal article10.2807/1560-7917.ES.2025.30.7.25001021025-496X39980423